GlassScriptPhysician profile
Carol A Burke
NPI 1588629554
$20,904.40
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $848 · 2021: $207 · 2022: $6,872 · 2023: $1,727 · 2024: $1,030 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Food and Beverage | $782.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $9,226.74 | 2019-2023 | Rebyota |
| Janssen Research & Development, LLC | $5,302.50 | 2022 | |
| Sebela Pharmaceuticals INC. | $2,650.00 | 2022-2023 | |
| Mallinckrodt Enterprises LLC | $950.00 | 2019 | |
| Almirall LLC | $900.00 | 2024 | |
| Provepharm INC. | $750.00 | 2020 | |
| Myriad Genetic Laboratories, INC. | $449.53 | 2021-2025 | Myrisk |
| Abbvie INC. | $270.52 | 2020-2024 | Linzess |
| Medtronic, INC. | $229.23 | 2022-2024 | Gi Genius |
| Genzyme Corporation | $119.13 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.42 | 2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $15.82 | 2023 | Dificid |
| Novo Nordisk INC | $12.33 | 2019 | |
| Shionogi INC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.